ExeVir is a clinical stage company developing single-domain antibody-based therapies that help patients ward off viral infections. Our lead candidate XVR011 is in accelerated development as a COVID-19 therapeutic. Our lead compound, an enhanced variant of VHH72-Fc binds to a unique epitope that is conserved in SARS-CoV-1 and SARS-CoV-2 viruses and this binding prevents these viruses from entering the cell. The importance of this approach is that it could be used both as a therapeutic and prophylactic. Therapeutic use could help slow viral replication in the lungs, reduce inflammation, and give patients valuable time to raise their own productive immune response. Prophylactic use could support the ringfencing of an outbreak, protect healthcare workers, caregivers and support those at increased risk of severe illness from Covid-19.
$ 2.5 Millions - $ 5 Millions
Leave a Reply